Clinical Practice Guideline for Primary Liver Cancer(2024 Edition)

Primary liver cancer is one of the common malignant tumors in China. According to the cancer statistics report in China for the year 2022, the incidence and mortality rates of primary liver cancer in our country rank 5th and 2nd, with 367 700 new cases and 316 500 deaths, respectively. In recent years, with the continuous development of diagnosis and treatment technology, high-level evidence-based medical evidence has emerged. To further standardize the diagnosis and treatment of liver cancer in China, the Department of Medical Administration, National Health Commission has specially commissioned the Oncology Branch of the Chinese Medical Association to work with multidisciplinary experts. They have referred to the latest research results in the diagnosis, staging, and treatment of liver cancer, combined with the clinical diagnosis and treatment practice of liver cancer in our country, and revised and updated the Clinical Practice Guideline for Primary Liver Cancer (2024 Edition). This guideline timely reflects the new progress and new concepts in the field of liver cancer diagnosis and treatment, and will provide the latest diagnostic and treatment basis for clinical physicians, better guide clinical practice, and improve the standardization level of liver cancer diagnosis and treatment in China.